Biomedtracker Q3 2017 Outlook Report

  • ID: 4418927
  • Report
  • Region: Global
  • 25 Pages
  • BMT
1 of 3

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. At the end of this report, we have included a list of Large Impact catalysts through Q3 2017.

Note: Product cover images may vary from those shown
2 of 3
  • Outcomes of the Large Impact Catalysts from the Q2 2017 Outlook Report
  • CTL019 for Acute Lymphocytic Leukemia (ALL) (NVS)
  • Mylotarg for Acute Myelogenous Leukemia (AML) (PFE)
  • Intepirdine for Alzheimer's Disease (AD) (AXON)
  • Biosimilar Trastuzumab (Mylan) for Breast Cancer (MYL)
  • Nerlynx for Breast Cancer (PBYI)
  • Lampalizumab for Dry Age-Related Macular Degeneration (Dry AMD) (Ophthalmology) (RHHBF)
  • Translarna for Duchenne Muscular Dystrophy (DMD) (PTCT)
  • Zorblisa for Epidermolysis Bullosa (FOLD)
  • ZYN-002 for Fragile X Syndrome (ZYNE)
  • Vyzulta for Glaucoma / Ocular Hypertension (Ophthalmology) (VRX)
  • Nurelin for Levodopa-Induced Dyskinesia (ADMS)
  • OPN-375 for Nasal Polyposis (OptiNose)
  • Imfinzi for Non-Small Cell Lung Cancer (NSCLC) (AZN)
  • Sirukumab for Rheumatoid Arthritis (RA) (JNJ)
  • Upadacitinib for Rheumatoid Arthritis (RA) (ABBV)
  • Brexanolone for Seizure Disorders (Epilepsy) (SAGE)
  • Endari for Sickle Cell Anemia (Emmaus)
  • Omadacycline for Skin and Skin-Structure Infections (Antibacterial) (PRTK)
  • Austedo for Tardive Dyskinesia (TEVA)
  • Patisiran for Transthyretin (TTR)-related Hereditary Amyloidosis (Familial Amyloid Polyneuropathy) (ALNY)
  • Meropenem-Vaborbactam for Urinary Tract and Reproductive Tract Infections (Antibacterial) (MDCO)
  • Q3 2017 Large Impact Drug Catalysts
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown